首頁
Stemline Therapeutics, Inc.

6月 2026Stemline Therapeutics, Inc.的市場佔有率分析

健康 > 生物技術和製藥

域名stemline.com

成立年份2003

僱員51 - 200

年度營收$25M - $50M

Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc.（包含公司地區）

stemline.com

查看更多網站流量與參與度資訊

Stemline Therapeutics, Inc.截至 6月 2026 的總收入為 25M - 50M

Stemline Therapeutics, Inc. 熱門網域產生的總收入

Stemline Therapeutics, Inc. 熱門網域 3 年內的總收入

Stemline Therapeutics, Inc. 熱門網域的總收入

stemline.com25M - 50M

透過銷售情報查看更多內容

Stemline Therapeutics, Inc.的熱門網域總造訪量

了解Stemline Therapeutics, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

stemline.com5.4K

透過銷售情報查看更多內容

Stemline Therapeutics, Inc.的熱門網域平均造訪時長

分析Stemline Therapeutics, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

stemline.com00:00:28

透過銷售情報查看更多內容

Stemline Therapeutics, Inc.的熱門網域平均頁面瀏覽量

了解Stemline Therapeutics, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

stemline.com1.47

透過銷售情報查看更多內容

Stemline Therapeutics, Inc.按網域劃分的熱門競爭對手

6月 2026的熱門類似網站，依相似度排名

vitals.com公司名Vitals僱員51 - 200總部美國, 新澤西州, Lyndhurst年度營收$25M - $50M訪問總量964.3K健康 > 醫學

使用的熱門技術Stemline Therapeutics, Inc.

这些是Stemline Therapeutics, Inc.顶级域名使用的行业网站技术

小工具 (4)

Twemoji

付費廣告 (2)

DoubleClick

音訊視訊媒體 (2)

YouTube

行動裝置 (2)

Meta Viewport

更多技術

9

檢視所有

新聞與訊號來自Stemline Therapeutics, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Nicacio leaves Stemline Therapeutics, Inc. as Senior Vice President, Head of Clinical Development and Global Medical Affairs.Prior to Protara, Dr. Nicacio served as Senior Vice President, Head of Clinical Development and Global Medical Affairs at Stemline Therapeutics, a subsidiary of the Menarini Group, where he was responsible for establishing and executing global strategies for solid tumor development.

新聞Stemline Therapeutics, Inc. attended event The European Hematology Association (EHA) 2026 Congress on Jun 14th '26.FLORENCE, Italy and NEW YORK, June 14, 2026 /PRNewswire/ - The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral[i] at The European Hematology Association (EHA) 2026 Congress.

新聞Stemline Therapeutics, Inc. attended event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 25th '26.FLORENCE, Italy and NEW YORK, May 25, 2026 /CNW/ - The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that new data related to elacestrant and tagraxofusp will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.